| 26.33 -0.06 (-0.23%) | 04-19 14:22 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 33.2 | 1-year : | 34.78 |
| Resists | First : | 28.43 | Second : | 29.78 |
| Pivot price | 27.26  |
|||
| Supports | First : | 26.25 | Second : | 21.84 |
| MAs | MA(5) : | 26.58 |
MA(20) : | 27.46 |
| MA(100) : | 32.06 |
MA(250) : | 30.56  |
|
| MACD | MACD : | -0.9 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 7.1 |
D(3) : | 8.2 |
| RSI | RSI(14): 35.3 |
|||
| 52-week | High : | 39.4 | Low : | 16.79 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SRDX ] has closed above bottom band by 20.3%. Bollinger Bands are 33.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 26.76 - 26.89 | 26.89 - 27.02 |
| Low: | 26 - 26.16 | 26.16 - 26.33 |
| Close: | 26.21 - 26.48 | 26.48 - 26.73 |
Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The IVD segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Fri, 19 Apr 2024
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1 - Business Wire
Fri, 12 Apr 2024
Surmodics (SRDX) Gains From Consistent Efforts to Boost R&D - Yahoo Movies Canada
Thu, 11 Apr 2024
Surmodics, Inc. (NASDAQ:SRDX) to Post Q1 2025 Earnings of ($0.23) Per Share, Zacks Research Forecasts - MarketBeat
Wed, 10 Apr 2024
Surmodics' (SRDX) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Wed, 10 Apr 2024
Q4 2025 EPS Estimates for Surmodics, Inc. Raised by Zacks Research (NASDAQ:SRDX) - MarketBeat
Wed, 20 Mar 2024
Here's Why You Should Hold Surmodics (SRDX) Stock for Now - Zacks Investment Research
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 14 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 3.7 (%) |
| Held by Institutions | 91.4 (%) |
| Shares Short | 447 (K) |
| Shares Short P.Month | 446 (K) |
| EPS | 0.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.57 |
| Profit Margin | 3.9 % |
| Operating Margin | -1.1 % |
| Return on Assets (ttm) | 4.4 % |
| Return on Equity (ttm) | 4.8 % |
| Qtrly Rev. Growth | 22.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 9.7 |
| EBITDA (p.s.) | 1.49 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 13 (M) |
| Levered Free Cash Flow | 12 (M) |
| PE Ratio | 67.66 |
| PEG Ratio | -3 |
| Price to Book value | 3.07 |
| Price to Sales | 2.71 |
| Price to Cash Flow | 30.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|